

REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14

Bring completed form to:
File Information Unit
Crystal Plaza Three, Room 1201
2021 South Clark Place
Arlington, VA
Telephone: (703) 368-2733

RECEIVED
SEP 20 2005
File Information Unit

In re Application of _____
Application Number 09-062 142 File # 04-17-98
Paper No. #7

I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified ABANDONED application, which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):

United States Patent Application Publication No. _____, page _____, line _____
United States Patent Number 6153 420 column _____, line _____, or
WIPO Pub. No. _____, page _____, line _____

Related Information about Access to Pending Applications (37 CFR 1.14):

Direct access to pending applications is not available to the public but copies may be available and may be purchased from the Office of Public Records upon payment of the appropriate fee (37 CFR 1.19(a)), as follows:
For published applications that are still pending, a member of the public may obtain a copy of:

- the file contents;
- the pending application as originally filed; or
- any document in the file of the pending application.

For unpublished applications that are still pending:

- (1) If the benefit of the pending application is claimed under 35 U.S.C. 119(a), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
the file contents;
the pending application as originally filed; or
any document in the file of the pending application.
- (2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
the pending application as originally filed.

Shoaib Chaguer
Signature

09-20-05
Date

Shoaib Chaguer
Typed or printed name

Registration Number, if applicable
203-553-0000
Telephone Number

FOR OFFICE USE ONLY
RECEIVED
Approved by [Signature]
File Information Unit



US006153420A

United States Patent [19]

Sheppard

[11] Patent Number: 6,153,420

[45] Date of Patent: Nov. 28, 2000

[54] SERINE PROTEASE POLYPEPTIDES AND MATERIALS AND METHODS FOR MAKING THEM

[75] Inventor: Paul O. Sheppard, Redmond, Wash.

[73] Assignee: ZymoGenetics, Inc., Seattle, Wash.

[21] Appl. No.: 09/072,384

[22] Filed: May 4, 1998

Related U.S. Application Data

[63] Continuation-in-part of application No. 09/062,142, Apr. 17, 1998, abandoned.

[60] Provisional application No. 60/044,185, Apr. 24, 1997.

[51] Int. Cl.⁷ C12N 9/64; C12N 15/57; C12N 15/62; C12N 15/70; C12N 15/79

[52] U.S. Cl. 435/226; 435/69.1; 435/69.7; 435/252.3; 435/25.33; 435/320.1; 435/417; 536/23.2; 536/23.4

[58] Field of Search 435/226, 69.1, 435/69.7, 252.3, 252.33, 320.1, 417; 536/23.2, 23.4

[56] References Cited

U.S. PATENT DOCUMENTS

5,460,950 10/1995 Barr et al. 435/69.1
 5,460,953 10/1995 Gerlitz et al. 435/226
 5,804,410 9/1998 Yamaoka et al. 435/69.1
 5,863,756 1/1999 Barr et al. 435/69.1

FOREIGN PATENT DOCUMENTS

95/14772 6/1965 WIPO.

OTHER PUBLICATIONS

Li, k., et al., GenBank nucleotide sequence Accession No. AF015287, "A novel serine protease from human umbilical vein endothelial cells, clone 10.16", 1997.

Clone ID 3655371, Incyte Pharmaceuticals, Inc., Oct. 6, 1997.

Clone ID 3655384, Incyte Pharmaceuticals, Inc., Oct. 6, 1997.

Clone ID 3656369, Incyte Pharmaceuticals, Inc., Oct. 6, 1997.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1995.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1995.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1995.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1995.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1996.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1997.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1997.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1997.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1997.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1997.

LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals, Inc., 1997.

(List continued on next page.)

Primary Examiner—Ponnathapu Achutamurthy

Assistant Examiner—William W. Moore

Attorney, Agent, or Firm—Gary E. Parker

[57] ABSTRACT

A novel serine protease is disclosed. The protease comprises a sequence of amino acid residues that is at least 95% identical to SEQ ID NO:2 from Ile, residue 111, through Asn, residue 373. Also disclosed are polynucleotide molecules encoding the protease, expression vectors containing the polynucleotides, cultured cells containing the expression vectors, and methods of making the protease. The protease can be used, inter alia, within industrial processes to degrade unwanted proteins or alter the characteristics of protein-containing compositions.

24 Claims, No Drawings